EC grants orphan drug status to Dicerna’s DCR-A1AT to treat congenital A1AT deficiency

This article was originally published here

The status has been provided to DCR-A1AT based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). A1AT deficiency

The post EC grants orphan drug status to Dicerna’s DCR-A1AT to treat congenital A1AT deficiency appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply